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Background: Over 850 million people worldwide and 200 million adults in Sub-Saharan Africa suffer from
malnutrition. Countries most affected by HIV are also stricken by elevated rates of food insecurity and malnutrition.
HIV infection and insufficient nutritional intake are part of a vicious cycle that contributes to immunodeficiency and
negative health outcomes. However, the effect of the overlap between HIV infection and undernutrition on the
immune response following antiretroviral initiation remains unclear. A possible explanation could be the lack of
consensus concerning the definition and assessment of nutritional status. Our objectives are to investigate the
existence of an association between undernutrition and immune response at antiretroviral treatment initiation and
the following year in low- and middle-income countries where malnutrition is most prevalent.
Methods/design: Our systematic review will identify studies originating from low- and middle-income countries
(LMICs) published from 1996 onwards, through searches in MEDLINE (PubMed interface), EMBASE (OVID interface),
Cochrane Central (OVID interface) and grey literature. No language restrictions will be applied. We will seek out
studies of any design investigating the association between the nutritional status (for example, undernourished
versus well nourished) and the immune response, either in terms of CD4 count or immune failure, in seropositive
patients initiating antiretroviral therapy or in their first year of treatment. Two reviewers will independently screen
articles, extract data and assess scientific quality using standardized forms and published quality assessment tools
tailored for each study design. Where feasible, pooled measures of association will be obtained through
meta-analyses. Results will be reported according to the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) Statement. This protocol has been registered in the PROSPERO database (registration
number: CRD42014005961).
Conclusion: Undernutrition and weight loss are prevalent amongst highly active antiretroviral therapy (HAART)-
treated patients in LMICs and contribute to excess early mortality. A possible intermediate pathway could be poor
immune reconstitution secondary to deficient nutritional status. In the face of limited access to second line
treatments, raising HIV resistance and cut backs to HIV programs, it is crucial to identify the factors associated with
suboptimal response and therapeutic failure in order to better customize the care strategies employed in LMICs.
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Malnutrition is a persisting public health issue affecting
over 850 million people worldwide and 200 million adults
in Sub-Saharan Africa (SSA) [1,2]. The term ‘malnutri-
tion’ is often used indifferently to refer both to undernu-
trition and overnutrition. In undernutrition, macro- and/
or micronutrient supply are continuously below mini-
mum dietary requirements, which leads to changes in
body composition and diminished function [3,4]. For the
purpose of this systematic review, we will focus on un-
dernutrition as a state of malnutrition.
Before the HIV epidemics, malnutrition was the first
cause of immunosuppression worldwide [5]. Micro- and
macronutrient deficiencies weaken the immune system
through atrophy of the thymus and lymphoid tissue, al-
teration of T cell subsets, decrease of T cell counts and
cytokine response [6,7]. In protein energy malnutrition
(PEM), cell-mediated and innate immunity [6,8] are par-
ticularly lessened, thereby increasing the risk of viral in-
fection (including HIV) and disease progression [9-11].
Furthermore, persistent malnutrition leads to an inflam-
matory state through decreased leptin levels [12] and al-
tered intestinal mucosa permeability which further
augments the organism’s vulnerability to infection [5].
Countries where food insecurity and malnutrition are
common are also stricken by high HIV incidence and
prevalence rates [13,14]. The effect of overlap between
HIV infection and undernutrition in low- and middle-
income countries (LMICs) on immunological function
remains unclear [2,14,15]. HIV is a cause of nutritional
deficiencies through its effect on nutrient absorption -
for example, HIV-mediated inflammation and induced
mucosal immune cell damage in the gastrointestinal
tract leads to diarrhea and malabsorption, decreased in-
take - for example, odynophagia induced by esophageal
candidiasis (an opportunistic infection (OI)) - limits the
capacity to feed oneself. Finally, HIV itself or associated
OI can result in increased energy expenditure [16-18].
As such, malnutrition and HIV coexist in a vicious per-
petuating cycle.
Increased availability of highly active antiretroviral
therapy (HAART) in LMICs has led to some improve-
ment of the nutritional status of patients [19-22]. How-
ever, for certain individuals, undernutrition and weight
loss persist despite therapy [17,23,24]. Just like with HIV,
HAART and malnutrition contribute to a deadly cycle.
Highly active antiretroviral therapy (HAART) leads to
increased requirements for macro- and micronutrients,
high metabolic demands [25] and low appetite [26]
which perpetuate undernutrition [27]. Simultaneously,
malnutrition exacerbates side effects [28-31], alters drug
pharmacokinetics [32], and impinges on adherence [33]
thereby limiting the beneficial effects of the therapy. Like
in ART-naive patients, suboptimal nutritional statusamongst those treated is associated with disease progres-
sion and early death [34-41]. As such, excess early mor-
tality in patients initiating treatment in LMICs compared
to high-income countries has been reported [42].
Despite theoretical and experimental evidence linking
malnutrition and altered immune function, there exists
no consensus concerning the impact of malnutrition on
the immune response in HIV patients receiving tri-
therapy. Numerous nutritional interventions have been
attempted in seropositive populations under antiretro-
viral treatment (ART) without convincing clinical re-
sults. As such, a recent systematic review investigating
nutritional interventions and clinical outcomes in high-,
middle- and low-income countries failed to show any
advantages in terms of CD4 or weight gain in those re-
ceiving food supplements [13]. In populations from
LMICs, research has failed to demonstrate an association
between lower CD4 counts and markers of undernutrition
amongst newly diagnosed seropositive individuals com-
pared to seronegative controls [43,44]. In populations
under combined antiretroviral treatment (cART), evidence
so far appears contradictory. As underlined by Soeters
(2008), a possible explanation for this absence of consen-
sus could be the lack of homogeneity in the definition and
conceptualization of malnutrition [4]. Various undernutri-
tion syndromes have been grouped under the umbrella of
malnutrition - protein-energy malnutrition (PEM), cach-
exia, sarcopenia, marasmus, kwashiorkor - each being the
result of different pathophysiological processes and each
leading to distinct morphological and biochemical modifi-
cations [4,45]. Furthermore, there exists no unique indi-
cator to capture malnutrition. As such, prevalence of
malnutrition amongst HIV patients varies according to
the instrument used [46]. In field studies, body compos-
ition is often evaluated using either body mass index
(BMI), mid-upper arm circumference (MUAC), skinfolds
(SK), or bioelectrical impedance (BIA); each method cap-
turing a different aspect of body composition. The simpli-
city and cheapness of anthropometric techniques has
made them popular in nutritional studies, independently
of their appropriateness [47]. Some authors indicate that
nutritional assessment should also include analysis of
biochemical nutritional parameters such as albumin and
C-reactive protein (CRP) to account for inflammation in
the establishment and maintenance of malnutrition [4,48].
Further evidence is required to clarify the association
between nutritional status and immunological outcomes.
For the purpose of this systematic review, we will use
the operationalized definition of malnutrition proposed
by Soeters (2008). In his model, Soeters attempts to
regroup different pathophysiological explanations and
consequences of malnutrition into one conceptual
framework. This model feeds onto the different defini-
tions that have been proposed to describe malnutrition.
Figure 1 PRISMA flow diagram. Source: Moher, D., et al., Preferred
reporting items for systematic reviews and meta-analyses: the PRISMA
statement. BMJ, 2009. 339: p.b2535.
Sicotte et al. Systematic Reviews 2014, 3:9 Page 3 of 8
http://www.systematicreviewsjournal.com/content/3/1/9We will focus on the clinical assessment of body com-
position and inflammatory activity [4]. For the former,
indicators investigated will include BMI, MUAC, SK,
and BIA (as a measure of body cell mass (BCM)). As for
the latter, markers investigated will include albumin,
hemoglobin and C-reactive protein (CRP). These mea-
sures will be contrasted with one measure of function,
namely the immune function. With this systematic re-
view we hope to provide clarification concerning the
cross-sectional and longitudinal associations between
undernutrition and immune response in seropositive pa-
tients receiving ART in LMICs.
Objectives and research questions
This systematic review is guided by the following re-
search hypotheses: a) macro-nutritional deficiencies in
HIV + individuals, either at time of treatment initiation
or in the first year of treatment, will lead to a defective
immune response to HAART independently of disease
stage, and b) the existence and strength of the associa-
tions observed between malnutrition and immune re-
constitution following ART initiation will vary with the
choice of nutritional marker.
Our aim is to investigate the existence of an associ-
ation between undernutrition and the immune response
following ART initiation in LMICs. To do so, we will
identify, assess and synthesize the literature from LMICs
a) to evaluate the cross-sectional relationship between
malnutrition and immune markers at treatment initi-
ation; b) to investigate the association between nutri-
tional indicators at time of treatment initiation and the
prospective immune response in the year after ART ini-
tiation and, c) to assess longitudinal co-variation be-
tween nutritional and immune trajectories in patients
under HAART for less than a year; and d) to establish
whether the associations highlighted in a), b), and c) vary
according to individual and/or subgroups of nutritional
indicators.
Methods
The guidelines proposed in the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
statement will be used as a template for the development
and execution of this review (Figure 1) [49]. The methodo-
logical choices described in this protocol have been
inspired by previously published work from members of
our group [50]. This systematic review protocol was regis-
tered with the PROSPERO database (registration number:
CRD42014005961).
Search strategy
The search strategies will be carried out by the research
team (MS, JA, and MVZ) and an expert librarian (DZ).
No language restriction will be enforced conditional tothe provision of an English abstract. Using specific med-
ical subject headings (MeSH) and text words, we will
identify studies originating from LMICs published from
1996 onwards (year the use of HAART became standard
[51]) through searches MEDLINE (PubMed interface),
EMBASE (OVID interface), all EBM reviews from OVID
(Cochrane Database of Systematic Reviews <2005 to
September 2013>, EBM Reviews - ACP Journal Club
<1991 to September 2013>, EBM Reviews - Database of
Abstracts of Reviews of Effects <third quarter 2013>,
EBM Reviews, Cochrane Central Register of Controlled
Trials <September 2013>, EBM Reviews - Cochrane
Methodology Register <third quarter 2012>, EBM
Reviews - Health Technology Assessment <third quarter
2013>, EBM Reviews - NHS Economic Evaluation
Database <third quarter 2013>), and Cochrane Central
(manual search). Details concerning our exact search
strategy are provided in Additional file 1. We will also
screen grey literature sources, namely: Social Care
Online; National Institute for Health and Clinical Excel-
lence (NICE); System for Information on Grey Literature
in Europe (OpenSigle); National Guideline Clearing
House; Health Development Agency; National Institutes
of Health; Research Service Delivery and Organization
Program (SDO); Research Register for Social Care; Google
Scholar and OpenGrey. Furthermore, we will search offi-
cial Websites of institutions active in the fields of HIV/
AIDS and nutrition, along with bibliographic references
of retrieved articles and reviews.
Our search strategy will combine the following subhead-
ings: 1) Nutrition/nutritional indicators; 2) Antiretroviral
treatment; 3) Immune response and 4) Low- and middle-
income countries. The terms ‘HIV’ and ‘AIDS’ will not be
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tions to be captured under the second theme. All articles
and reports retrieved during the identification phase will
be combined in an Endnote file. Duplicates will then be
extracted. Endnote entries will be further filtered to re-
move all pediatric and peri/postpartum literature. Details
concerning these steps can be found in Additional files 1
and Additional file 2.
Study inclusion criterions
Participants and setting
We will identify studies investigating the immune re-
sponse according to nutritional markers in non-pregnant,
treatment-naive, HIV-1 infected adults Participants will ei-
ther be initiating HAART - a regimen consisting of three
antiretroviral molecules - or receiving HAART for less
than a year. All regimen composition will be considered.
Malnutrition in LMICs is a great public health concern
with prevalence as high as 69% in the general population
[52]. For this reason, we will focus on studies originating
from these settings. We will use The World Bank Group’s
classification to identify those countries (Additional file 2)
[53].
Types of designs
We will include experimental studies, namely, random-
ized controlled trials (RCTs) and cluster-randomized
trials (CRTs); quasi-experimental studies including quasi-
randomized trials, controlled before-after studies (CBAs)
and interrupted time series studies (ITSs); as well as ob-
servational studies including cohort, case-control and
cross-sectional studies.
Study exclusion criteria
Studies assessing children or adolescent, pregnant
women, individuals either co-infected or solely infected
with HIV-2 will be excluded. Also, patients that are not
about to start treatment or who have been on HAART
for longer than a year will not be considered. Studies
strictly reporting qualitative results will not be retained
Outcomes
Our primary outcome will be the immune response in the
year following ART initiation either in terms of CD4
counts or percentage, or change in CD4 count between
visits (either categorized or in continuous form). Second-
ary outcomes will include: 1) immune treatment failure
and 2) time to immune failure after ART initiation. All
definitions of immune treatment failure will be considered
providing they are solely based on CD4 response.
Determinants
Our main exposure will be malnutrition at time of treat-
ment initiation and in the first year of treatment. Assuggested by Soeters (2008), indicators of body compos-
ition and inflammatory activity will be considered,
namely: weight, BMI, MUAC, SK, and BIA (a measure
of BCM, %BCM, phase angle, extracellular water (ECW),
intracellular water (ICW) and fat-free mass (FFM)) for
the former category; and albumin, hemoglobin and
C-reactive protein (CRP) for the latter [4]. Variables
other than weight should be categorized according to
validated cut-off values capable of identifying malnour-
ished individuals in the populations at hand. Interpret-
ation of BIA parameters should be made in relation to
age and BMI-adapted reference values for each given
parameter. Only longitudinal variations in weight follow-
ing ART initiation will be considered. Wasting syndrome
will not be an item of interest because it refers to a clus-




Study selection will be done in two stages. First, two inde-
pendent researchers (JA (epidemiologist, PhD) and MS
(PhDc)) will screen entries on titles and abstracts for rele-
vance and presence of the selection criteria listed above.
Articles will then be classified as i) included, ii) excluded
or iii) uncertain. The inter-rater agreement will be com-
puted using Cohen’s Kappa before initiating the second
stage. A sample size of 226 abstracts will be required for
the calculations assuming a significance level α of 0.05
(z = 1.96), a significance level β of 0.20 (z = 0.842), κ0 =
70%, κ1 = 90%, and a positive rating of 10% per rater [55].
Second, the full text articles of selected abstracts (records
categorized as included or uncertain) will be independ-
ently reviewed for further eligibility analysis using a stan-
dardized form with explicit inclusion and exclusion
criteria (Additional file 3). Discordance between the au-
thors will be resolved by consensus or through discussion
with a senior epidemiologist (MVZ).
Data collection process
We wish to retrieve quantitative results exploring the as-
sociation between the nutritional status and immune re-
sponse as described in our objectives. As such, an
association of measure - either frequency ratio or statis-
tical test comparing a marker of malnutrition contained
in the list mentioned above and a measure of the im-
mune response - has to be provided. Survival analyses
will also be considered - for example, time to immune
failure according to nutritional status at baseline. Re-
viewers will use a standardized data collection form to
extract data such as study characteristics (country, set-
ting, year of publication, study design, sample size); par-
ticipants’ characteristics (age, sex, ART-naive or not,
time since initiation of ART, type of ART regimen, other
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in CD4 counts, immune failure, definition of immune
failure (if applicable)); and measures of the association
between immune response and nutritional indicators with
information concerning adjustments (univariate versus
multivariate analyses, confounding variables) (Additional
file 3). Initially, the form will be piloted on a random sam-
ple to examine its reliability in data abstraction. According
to the results, and if necessary, the form will be refined. JA
and MS will independently extract the data. Unsettled
disagreements will be resolved by discussion with a senior
reviewer (MVZ).
Assessment of risk of bias and methodological quality
The scientific quality of individually selected articles will be
appraised to identify studies with the best internal validity.
To do so, standardized quality assessment tools tailored to
each study design will be used to best assess methodo-
logical quality and risk of spurious associations. The
Cochrane Collaboration’s Risk of Bias Tool (CCRBT) [56]
and Cochrane Effective Practice and Organization of Prac-
tice (EPOC) Risk of Bias Tool [57] will be used for RCTs
and quasi-experimental designs respectively. For cohort,
case control and cross-sectional studies, we will use the
Effective Public Health Practice Project (EPHPP) Quality
Assessment Tool for Quantitative Studies with extended
selection bias assessment. The latter encompasses the prin-
cipal quality items identified by the Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) Statement [58]. As suggested by Groenwold and
Rovers (2010), adherence to the STROBE statement as-
sures that the presentation of study characteristics is done
to facilitate scientific appraisal [59]. Domains of import-
ance will include: explicit identification of the study popu-
lation, methods of outcome and determinant assessment,
attrition rate and losses to follow-up, incomplete outcome
data, as well as other sources of bias. Quality assessment
will be carried out independently by each reviewer (JA and
MS). Disagreements will be resolved by discussions be-
tween reviewers and with a senior advisor (MVZ) if ne-
cessary. Inter-rater reliability will be computed using
Cohen’s Kappa to measure the interobserver agreement.
Studies investigating nutritional factors and immune re-
sponse in LMIC are greatly prone to publication bias due
to language barriers, limited funding, limited interest, and
so on. For this reason, grey literature will be extensively
scrutinized to uncover relevant data. Furthermore, authors
of the retained articles will be contacted directly to insure
that no negative results have been withheld from publish-
ing. These issues will be discussed in length in the system-
atic review. If enough studies within any given design
(cross-sectional, case-control, cohorts) are identified to
conduct a meta-analysis, funnel plots and trends tests will
be used to assess publication bias.Data synthesis
If the studies uncovered allow it, associative measures be-
tween malnutrition and immune indicators will be pooled
through meta-analyses using The Cochrane Group’s
Review Manager software (RevMan 5.1) [60]. Data will be
combined and analyzed by markers of undernutrition
(BMI, MUAC, SK, BIA, albumin, hemoglobin or CRP)
and/or subgroups of indicators (body composition versus
inflammation). Where possible, and as suggested by Deeks
(2002) and the Cochrane Handbook for Systematic Reviews
of Interventions, summarized measures of effectiveness
will be presented as such: for dichotomized outcomes (for
example, presence/absence of immune failure), odds ratios
or risk ratios and their respective confidence intervals will
be used. For continuous outcomes, mean difference and
its associated standard error will be used. For longitudinal
studies, we will present risk ratios or hazard ratios. Odds
ratios will be used in cross-sectional or case-control stud-
ies. Categorical variables will be meta-analyzed in a dichot-
omous form [61,62].
Graphical summaries of study estimates and aggre-
gated direct estimates will be presented for each nutri-
tional determinant if multiple studies are uncovered. We
will not perform indirect comparisons. We believe that
such analyses are inappropriate in our case due to the
numerous potential confounders and effects modifiers
unaccounted for in the methodology and/or analyses
that are likely to differ between settings and studies.
The statistical heterogeneity across studies will be inves-
tigated using the I2 statistic. This statistic describes the
percentage of total variation between studies that is due to
sampling rather than methodological error [63]. Hetero-
geneity will be considered statistically significant if I2 is
over 50%. In the case of substantial heterogeneity, random,
rather than fixed-model effects will be used [64]. Separate
sensitivity and/or sub-analyses will be conducted to assess
heterogeneity across methodological factors such as study
design, overall study quality, length of follow-up, geo-
graphical region or type of variables. If possible, we will
carry out separate meta-analyses of adjusted versus non-
adjusted (or insufficiently adjusted) association measures.
Reasons for clinical heterogeneity will be explored qualita-
tively a priori based on known literature. However, many
known and unknown confounders and effect modifiers
are likely to affect the association between malnutrition
and immune response. For instance, it is possible that the
presence of other viral or bacterial infections, detected or
not, modifies the strength of the associations between
malnutrition and response to HAART. Where conditions
impede meta-analyses, data will be synthesized narratively.
Our results will be presented according to the PRISMA
Statement [49].
Finally, and if possible, quality of the overall evidence
will be evaluated by aggregating quality ratings of
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system [65].Discussion
Although increased availability of first line HAART in
LMICs has significantly reduced mortality and morbidity
amongst people living with HIV/AIDS (PLA), undernutri-
tion and weight loss persist [17,23,24]. Both act as strong
predictors of excessive early mortality [35,37,40,41]; pos-
sibly through poor immune reconstitution secondary to
deficient nutritional status in PLA. With the rapid scale-
up of ART programs, concerns have also been growing
about the sustainability and effectiveness of such programs
[14]. Currently, funds injected into HIV programs are
diminishing and access to second line regimens in LMICs
continues to be restricted. There is thus a growing need to
optimize therapeutic success of first line ART, delay the
need for therapeutic switch, and limit rates of resistance,
which are on the rise, in those regions [66].
With this systematic review we hope to clarify the as-
sociation between malnutrition and immunological
response to HAART in HIV + population. More specific-
ally, we wish to establish whether ART drug treatment is
suboptimal in the undernourished. Our clinical goals are
to: 1) facilitate the identification of patients at greater risk
of inadequate immune response; and 2) help in differenti-
ating between malnutrition in PLA and more advanced
disease (that is greater inflammatory process). We believe
our results will contribute to informing physicians and
policy makers in settings where care strategies have to be
optimized to limit therapeutic failure by shedding some
light on the processes that contribute to suboptimal
therapeutic response. We are aware that the studies we
will uncover will present different limitations due to the
complexity of the association of interest and the chal-
lenges associated with nutritional research in vulnerable
groups. These limitations, as well as bias and precision
of estimates, will be discussed in length in our review
giving special attention to the possible publication bias
of studies conducted in settings with limited resources
and in non-English speaking populations by non-English
speaking researchers. As suggested by the PRISMA
statement, we wish this protocol to be part of an itera-
tive process that respects accepted and transparent
reporting methods [49].Additional files
Additional file 1: Search strategy MEDLINE, EMBASE, and Cochrane
Central.
Additional file 2: Endnote file manipulations.
Additional file 3: Data collection form.Abbreviations
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